NASDAQ:CARA Cara Therapeutics (CARA) Stock Price, News & Analysis → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free CARA Stock Alerts $0.75 -0.06 (-7.41%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$0.75▼$0.8050-Day Range$0.66▼$0.9552-Week Range$0.50▼$4.45Volume253,065 shsAverage Volume280,610 shsMarket Capitalization$41.01 millionP/E RatioN/ADividend YieldN/APrice Target$11.12 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Cara Therapeutics alerts: Email Address Cara Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside1,382.5% Upside$11.12 Price TargetShort InterestBearish5.62% of Float Sold ShortDividend StrengthN/ASustainability-1.39Upright™ Environmental ScoreNews Sentiment-0.15Based on 14 Articles This WeekInsider TradingSelling Shares$5,237 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.23) to ($0.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.51 out of 5 starsMedical Sector283rd out of 922 stocksPharmaceutical Preparations Industry121st out of 423 stocks 3.4 Analyst's Opinion Consensus RatingCara Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCara Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Cara Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.62% of the float of Cara Therapeutics has been sold short.Short Interest Ratio / Days to CoverCara Therapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldCara Therapeutics does not currently pay a dividend.Dividend GrowthCara Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCara Therapeutics has received a 61.20% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Clinical research services for physical health" and "Opioid painkillers" products. See details.Environmental SustainabilityThe Environmental Impact score for Cara Therapeutics is -1.39. Previous Next 1.6 News and Social Media Coverage News SentimentCara Therapeutics has a news sentiment score of -0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Cara Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for CARA on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat Follows4 people have added Cara Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,237.00 in company stock.Percentage Held by InsidersOnly 3.10% of the stock of Cara Therapeutics is held by insiders.Percentage Held by Institutions44.66% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cara Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cara Therapeutics are expected to grow in the coming year, from ($1.23) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cara Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cara Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCara Therapeutics has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cara Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. About Cara Therapeutics Stock (NASDAQ:CARA)Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Read More CARA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CARA Stock News HeadlinesMay 18 at 2:17 AM | americanbankingnews.comHC Wainwright Comments on Cara Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:CARA)May 17 at 6:34 AM | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Cara Therapeutics (NASDAQ:CARA)May 15, 2024 | americanbankingnews.comCara Therapeutics (NASDAQ:CARA) Rating Reiterated by Needham & Company LLCMay 14, 2024 | finanznachrichten.deCara Therapeutics, Inc.: Cara Therapeutics Reports First Quarter 2024 Financial ResultsMay 14, 2024 | markets.businessinsider.comIn-Depth Examination Of 5 Analyst Recommendations For Cara TherapeuticsMay 13, 2024 | investorplace.comCARA Stock Earnings: Cara Therapeutics Misses EPS, Beats Revenue for Q1 2024May 13, 2024 | chron.comCara: Q1 Earnings SnapshotMay 13, 2024 | globenewswire.comCara Therapeutics Reports First Quarter 2024 Financial ResultsMay 11, 2024 | americanbankingnews.comCara Therapeutics (CARA) to Release Quarterly Earnings on MondayMay 6, 2024 | globenewswire.comCara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024May 2, 2024 | yahoo.comCara Maria Hatches a Revenge Plot on 'The Challenge: All Stars' Season 4May 1, 2024 | msn.comComedian Cara Connors on Coming Out, Being a “Sassy Gay Cowboy,” and Dating Gen ZApril 30, 2024 | yahoo.comTime to Meander Through Cara Delevingne’s Dating History 😬April 29, 2024 | yahoo.comNeighbours' Remi and Cara caught out over Felix and JJ secretApril 28, 2024 | msn.comCara Delevingne's House Fire Cause Still A Mystery As LAFD Closes InvestigationApril 26, 2024 | bizjournals.comCara Porto-Osborn of Young + Wright ArchitecturalApril 24, 2024 | finance.yahoo.comOruka Therapeutics Expands Leadership Team, Naming Joana Goncalves, MBChB, as Chief Medical OfficerApril 20, 2024 | usatoday.comBeing the Marquette women's basketball coach means a lot to Cara Consuegra. She's ready to rebuild.April 18, 2024 | money.usnews.comCara Therapeutics IncApril 14, 2024 | msn.comThe Challenge: Zach Nichols reacts to seeing Cara Maria Sorbello back for All Stars 4April 14, 2024 | msn.comThe Challenge’s Cara Maria Sorbello thought All Stars 4 castmates would reunite due to ‘hatred’ of herApril 14, 2024 | msn.comNY GOP moves to knock ‘The Biggest Loser’ trainer Cara Castronuova out of Senate primaryApril 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cara Therapeutics: Promising Prospects for Oral Difelikefalin in Notalgia Paresthetica TreatmentApril 11, 2024 | investing.comCara Therapeutics CMO sells shares worth over $2,000April 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cara Therapeutics Amidst Promising Korsuva Ph 2/3 Program and Market PotentialSee More Headlines Receive CARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/04/2024Today5/18/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CARA CUSIPN/A CIK1346830 Webwww.caratherapeutics.com Phone(203) 406-3700Fax203-567-1510Employees55Year FoundedN/APrice Target and Rating Average Stock Price Target$11.12 High Stock Price Target$25.00 Low Stock Price Target$3.60 Potential Upside/Downside+1,382.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118,510,000.00 Net Margins-723.49% Pretax Margin-723.49% Return on Equity-174.15% Return on Assets-105.26% Debt Debt-to-Equity RatioN/A Current Ratio5.38 Quick Ratio4.43 Sales & Book Value Annual Sales$16.94 million Price / Sales2.42 Cash FlowN/A Price / Cash FlowN/A Book Value$0.55 per share Price / Book1.36Miscellaneous Outstanding Shares54,676,000Free Float52,981,000Market Cap$41.01 million OptionableOptionable Beta0.74 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Christopher A. Posner (Age 54)President, CEO & Director Comp: $1.2MMr. Ryan D. Maynard (Age 55)Chief Financial Officer Comp: $511.7kDr. Joana Goncalves M.D. (Age 50)Chief Medical Officer Comp: $747.25kDr. Derek T. Chalmers D.Sc. (Age 60)Ph.D., Co-Founder & Senior Advisor Comp: $580.93kDr. Iris Francesconi Ph.D.Chief Strategy Officer & Head of Investor RelationsMr. Scott M. Terrillion (Age 61)Chief Compliance Officer, General Counsel & Corporate Secretary Comp: $689.63kMs. Beth Weinberg R.Ph.Senior Vice President of Regulatory Affairs & QAMr. Matthew MurphyManager of Investor RelationsMore ExecutivesKey CompetitorsLexaria BioscienceNASDAQ:LEXXXilio TherapeuticsNASDAQ:XLOUnicycive TherapeuticsNASDAQ:UNCYSensei BiotherapeuticsNASDAQ:SNSEProMIS NeurosciencesNASDAQ:PMNView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 149,809 shares on 5/10/2024Ownership: 4.539%Acadian Asset Management LLCSold 26,242 shares on 5/10/2024Ownership: 0.611%Marquette Asset Management LLCBought 94,238 shares on 5/7/2024Ownership: 0.172%Christopher PosnerSold 3,936 sharesTotal: $2,952.00 ($0.75/share)Rosalind Advisors Inc.Bought 1,548,893 shares on 4/25/2024Ownership: 2.833%View All Insider TransactionsView All Institutional Transactions CARA Stock Analysis - Frequently Asked Questions Should I buy or sell Cara Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CARA shares. View CARA analyst ratings or view top-rated stocks. What is Cara Therapeutics' stock price target for 2024? 4 brokerages have issued 12 month target prices for Cara Therapeutics' stock. Their CARA share price targets range from $3.60 to $25.00. On average, they expect the company's share price to reach $11.12 in the next year. This suggests a possible upside of 1,382.5% from the stock's current price. View analysts price targets for CARA or view top-rated stocks among Wall Street analysts. How have CARA shares performed in 2024? Cara Therapeutics' stock was trading at $0.7430 on January 1st, 2024. Since then, CARA stock has increased by 1.0% and is now trading at $0.7501. View the best growth stocks for 2024 here. When is Cara Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our CARA earnings forecast. How were Cara Therapeutics' earnings last quarter? Cara Therapeutics, Inc. (NASDAQ:CARA) released its quarterly earnings results on Monday, March, 4th. The biopharmaceutical company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.02. The biopharmaceutical company earned $3 million during the quarter, compared to analyst estimates of $2.34 million. Cara Therapeutics had a negative trailing twelve-month return on equity of 174.15% and a negative net margin of 723.49%. During the same quarter last year, the firm posted ($0.56) EPS. What ETF holds Cara Therapeutics' stock? Amplify Seymour Cannabis ETF holds 65,538 shares of CARA stock, representing 0.15% of its portfolio. What other stocks do shareholders of Cara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY). Who are Cara Therapeutics' major shareholders? Cara Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.54%), Rosalind Advisors Inc. (2.83%), Acadian Asset Management LLC (0.61%), Marquette Asset Management LLC (0.17%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Christopher Posner, Derek T Chalmers, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Ryan D Maynard, Scott Terrillion and Thomas Charles Reilly. View institutional ownership trends. How do I buy shares of Cara Therapeutics? Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CARA) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.